Vaccitech creates ways to treat and prevent disease

Learn More
3

Learn more Vaccitech creates ways to treat and prevent disease Learn more Prostate cancer is the most common cancer in men Learn more Vaccitech helps people lead longer, healthier lives Learn more Vaccitech is dedicated to improving global health

life at vaccitech

Our Mission

Image: NIAID

Treating and Preventing Disease

We develop T cell immunotherapeutic products to improve global health

Vaccitech is a spin-out company from the University of Oxford’s Jenner Institute, one of the most prestigious vaccine research centres in the world.

5

About Vaccitech

5

Our Approach

5

Meet Our Team

Vaccitech Ltd and the University of Oxford today announce an agreement with the UK-based global biopharmaceutical company AstraZeneca for the further development, large-scale manufacture and potential distribution of the COVID-19...
 Vaccitech and Oxford University announce landmark partnership with AstraZeneca for the development and large-scale distribution of the COVID-19 vaccine candidate Oxford, UK - Vaccitech announces today that its scientific founders at the Jenner Institute, University of Oxford, have begun testing a COVID-19 vaccine in human volunteers. Around 1,110 people will...
 Oxford COVID-19 vaccine begins human trial stage Oxford, UK – 30th March 2020  Vaccitech Ltd, a clinical stage biopharmaceutical company developing immunotherapies to treat infectious diseases and cancer, announced today that its Chief Executive Officer, Bill Enright, will...
 Vaccitech to Present at Solebury Trout Virtual Investor Conference Oxford, UK – Vaccitech Limited and the University of Oxford today announce initial efficacy and safety data for ADVANCE, a Phase 2a study testing VTP-800, an immunotherapeutic product candidate in...
 Vaccitech and Oxford University Announce Promising Phase 2a Data on Prostate Cancer Immunotherapy To assist with the coordination and oversight of cross-functional activities to support the Vaccitech portfolio of research and development programmes. All activities carried out within allocated time, and agreed costs...
 Vacancy: Clinical Programme Lead Oxford, UK – Vaccitech Ltd, a clinical-stage T cell immunotherapy company developing products to treat cancer and chronic infectious diseases, announces top line Phase 2 data and plans for its recombinant...
 Phase 2 Clinical Results for Vaccitech’s Universal Influenza A Vaccine
PROTECTED TECHNOLOGY

Teaching the immune system to confront deadly infections

Traditional vaccine technology creates a pronounced antibody response to the infectious agent. Vaccitech aim to induce potent and durable T cell responses from the cellular immune system.

5

Our Technology

5

Our Portfolio

5

Our Careers